Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia
about
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsTreating Negative Symptoms in Schizophrenia: an UpdateBrain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter SystemsHas an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophreniaSSR504734 enhances basal expression of prepulse inhibition but exacerbates the disruption of prepulse inhibition by apomorphine.Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis.Clinical and biochemical study of d-serine metabolism among schizophrenia patients.A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic PathwayReviewing the ketamine model for schizophrenia.Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development.Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primatesA computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance.Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.In vitro Characterization of a small molecule inhibitor of the alanine serine cysteine transporter -1 (SLC7A10).Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study.Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia.Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex.A quantitative system pharmacology computer model for cognitive deficits in schizophreniaMMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study).Multi-regression analysis revealed a relationship between l-serine and methionine, a component of one-carbon metabolism, in the normal control but not in the schizophrenia.Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trialsEffects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophreniaEffects of sarcosine and N, N-dimethylglycine on NMDA receptor-mediated excitatory field potentials.Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulatorsGlutamatergic transmission in schizophrenia: from basic research to clinical practiceD-serine and schizophrenia: an update.Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.Current and future treatment modalities in schizophrenia: novel antipsychotic drugs and cognitive therapy.The neurobiology and treatment of first-episode schizophrenia.Emerging drugs for schizophrenia: an update.Drug repurposing and emerging adjunctive treatments for schizophrenia.Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin.Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine.Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward.Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation.
P2860
Q22241447-2B038D2D-B51A-4B46-8649-4EB7C729103EQ26744805-6720275C-83FC-4390-97FC-CDC27AB210F5Q26786247-FE924F73-C49C-4E5C-AE6E-32BC5F584954Q28275290-FD0181B8-1845-4B79-B5E5-461149BC8522Q30427289-49126A2C-49B1-4781-AE65-512EB2F05D99Q30685335-46992086-CC36-43F6-AC22-84D0C7943F95Q30712278-A3244898-3CD0-414B-9F47-15B900F2CE05Q33565101-3320F204-D397-4BB7-A35D-2A24D85DFBD7Q33607904-E823711C-B9D0-4295-A79F-2E08889217A1Q34046060-658557A8-0078-4256-A219-668EEDD438F7Q34323711-1B9E9A53-FDF8-4270-9B50-DEEEEE79C85BQ34357077-407D2C5E-DD4A-48AA-839A-F0A58E3E0B47Q34377319-10A48231-AEE2-4368-B133-16160AEED969Q34381226-17B183EE-0A2D-4C68-BC9B-F9ED67E8EB48Q34640811-C8F7F788-1036-48CE-90F5-4E5491A70FD5Q35050885-44AD20B6-6FDA-4ECB-9559-1F89B76D28CAQ35167939-5ACCA787-04EE-475F-A4DB-F5FAB9CED4A0Q35802177-70A7A284-2DEA-4545-8632-AB77D676FCBCQ36246819-4B06F981-7C2F-4922-8C07-8E4B0D0389A1Q36247426-4BF3BA54-F5AE-4327-936B-AD409EBD38FFQ36795559-A0CED31E-4945-49AF-A270-29FA1051079CQ37134495-B18EEBC1-CABF-44A6-95DF-03298F7B9B72Q37224256-521A2925-4DEB-4653-B9FA-9CE753A4BA25Q37228346-20CE493E-FD17-4B0A-B3C0-54DD16A10374Q37438631-A8A48F83-B348-4EBC-97FD-BD41786251CBQ37673343-317EBB9D-A65B-49E0-AB09-38E3F6352826Q37978091-A65DBE7A-6DD3-459F-80E4-59C38553CD36Q37980657-E0762394-41B3-4938-8D8B-02CEA30BDF30Q38031285-F223F7C7-DB84-47B5-81DE-5EA207561A3FQ38032249-0B1A0C5E-8452-429D-A7AD-7CB3FA67DB05Q38151703-9B1E72E0-D39C-46DC-986F-6C19C5A1DA34Q38168861-C71C53F8-E15F-4360-9504-98CA473F002DQ38232366-0C29B855-6D2A-4BFF-837A-CA2A38DF3A77Q38252404-F1B51F9C-6C9C-41E7-B584-795C451EFDA9Q38417631-21BC0A09-A44F-4FBE-83AD-6156A65344E7Q38647035-95D56970-2AA9-4692-83B4-661C2216DBF8Q38767228-34CC0E14-7983-4273-AD40-A1FC19AA869FQ38917991-3AE04215-A4B8-4A71-8320-CF6F079EF902Q39062177-07F311DB-C76B-4E8C-A791-571470F9E0ACQ40448883-D6E4BBB7-532C-4830-BE53-F1925043F8C3
P2860
Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Meta-analysis of the efficacy ...... ators in chronic schizophrenia
@ast
Meta-analysis of the efficacy ...... ators in chronic schizophrenia
@en
Meta-analysis of the efficacy ...... ators in chronic schizophrenia
@nl
type
label
Meta-analysis of the efficacy ...... ators in chronic schizophrenia
@ast
Meta-analysis of the efficacy ...... ators in chronic schizophrenia
@en
Meta-analysis of the efficacy ...... ators in chronic schizophrenia
@nl
prefLabel
Meta-analysis of the efficacy ...... ators in chronic schizophrenia
@ast
Meta-analysis of the efficacy ...... ators in chronic schizophrenia
@en
Meta-analysis of the efficacy ...... ators in chronic schizophrenia
@nl
P2860
P3181
P1433
P1476
Meta-analysis of the efficacy ...... ators in chronic schizophrenia
@en
P2093
Surendra P Singh
Vidhi Singh
P2860
P304
P3181
P356
10.2165/11586650-000000000-00000
P407
P577
2011-10-01T00:00:00Z
P6179
1051181095